United Therapeutics (NSDQ:UTHR) announced today that it launched its Remunity pump for Remodulin in patients with pulmonary arterial hypertension (PAH).
Research Triangle Park, N.C.-based United Therapeutics’ Remunity pump initially received FDA clearance in May 2019 for patient filling, adding another 510(k) clearance in February 2020 to enable cassettes to be prefilled with Remodulin by contracted specialty pharmacies in an effort to increase convenience for patients, according to a news release.
The Remunity pump for Remodulin injection is indicated for the continuous subcutaneous delivery of Remodulin in adults greater than 22 years of age.
Remunity’s cassettes contain enough drug for up to three days and arrive from the specialty pharmacy prefilled to eliminate the need for a patient to mix or fill. The water-resistant, small device is programmed using a wireless remote to increase safety and simplicity of use.
“We are excit…